Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.935996
Abstract: In patients with hypereosinophilic syndrome (HES), mepolizumab reduces the incidence of HES-related clinical signs and symptoms (flares). However, reports characterizing flare manifestations are limited. The double-blind, parallel-group 200622 trial (NCT02836496) enrolled patients ≥12 years old… read more here.
Keywords: impact mepolizumab; disease flares; patients hypereosinophilic; hypereosinophilic syndrome ... See more keywords